TheraNovis

History

Introduction to the development history and key milestones of TheraNovis

History & Milestones

테라노비스가 핵심 바이오 기술을 바탕으로 이루어온 혁신과 검증된 가치 지표를 투명하게 공유합니다.

2021
Founded
6+
Gov. Grants
₩15B+
Total Raised
10+
Partnerships

2025

Launch of Semi-Automated Multiplex Staining System

Secured KRW 220M in funding from a private investment fund

2024

Strategic MOU signed with AtheonBio

Strategic MOU signed with Intec Scientific

Selected for MOTIE Materials & Components Technology Development Program (KRW 10B)

Initiated establishment of Boston, USA liaison office

Secured KRW 1B in Strategic Investment (SI) from IntekPlus

Launch of Skin GeneCurator skin condition assessment service

2023

Secured KRW 300M in TIPS Investment

Secured KRW 336M in Strategic Investment (SI)

Selected for MSS Deep-Tech TIPS Program (KRW 1.5B)

Selected for Seoul-type TIPS Program (KRW 400M)

Selected for Medical Device Industry Transition Infrastructure Program

Official Launch of Phenoview (now AstraTSA)

2022

Executing the Regional Specialized Industry Development Program (MSS)

Selected for PNU Yangsan Bio Core Facility Program (KRW 600M)

Selected for the KIBO Tech-Bridge Program

Selected for the Asan Medical Center Incentive Program

2021

TheraNovis Co., Ltd. Established

MOU Signed with BioActs and Six Partner Organizations

Established Corporate R&D Centers (Hanam / Yangsan)

Continuous leap forward as a leading global diagnostic platform company